Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models

Journal of Clinical Investigation

Volumn 119, Issue 11, 2009, Pages 3356-3372

  Maione, Federica ^a   Molla, Fabiola ^b   Meda, Claudia ^a   Latini, Roberto ^b   Zentilin, Lorena ^c   Giacca, Mauro ^c   Seano, Giorgio ^a   Serini, Guido ^a,d   Bussolino, Federico ^a,d   Giraudo, Enrico ^a,d  

^a UNIVERSITY OF TURIN   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SEMAPHORIN 3A; SEMAPHORIN 3F;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL; CELL DENSITY; CELL SURVIVAL; CELL TYPE; CONTROLLED STUDY; GENE EXPRESSION; GENE TRANSFER; MOUSE; NONHUMAN; PANCREAS ISLET CELL TUMOR; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR VASCULARIZATION;

ADENOMA, ISLET CELL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD29; CELL HYPOXIA; CELL MOVEMENT; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SEMAPHORIN-3A; UTERINE CERVICAL NEOPLASMS;

EID: 70449428715     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI36308     Document Type: Article

References (71)

1. Folkman, J. 2006. Angiogenesis. Annu. Rev. Med. 57:1-18.
2. Jain, R.K. 2005. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 307:58-62.
3. Inoue, M., Hager, J.H., Ferrara, N., Gerber, H.P., and Hanahan, D. 2002. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell. 1:193-202. (Pubitemid 41039165)
4. Jain, R.K., Duda, D.G., Clark, J.W., and Loeffler, J.S. 2006. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3:24-40. (Pubitemid 43108832)
5. Casanovas, O., Hicklin, D.J., Bergers, G., and Hanahan, D. 2005. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 8:299-309. (Pubitemid 41443415)
6. Fischer, C., et al. 2007. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 131:463-475. (Pubitemid 350007692)
7. Winkler, F., et al. 2004. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 6:553-563. (Pubitemid 40017699)
8. Carmeliet, P., and Tessier-Lavigne, M. 2005. Common mechanisms of nerve and blood vessel wiring. Nature. 436:193-200. (Pubitemid 41021263)
9. Bussolino, F., Valdembri, D., Caccavari, F., and Serini, G. 2006. Semaphoring Vascular Morphogenesis. Endothelium. 13:81-91.
10. Serini, G., et al. 2003. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature. 424:391-397. (Pubitemid 36917481)
11. Bielenberg, D.R., Pettaway, C.A., Takashima, S., and Klagsbrun, M. 2006. Neuropilins in neoplasms: expression, regulation, and function. Exp. Cell Res. 312:584-593. (Pubitemid 43290335)
12. Kessler, O., et al. 2004. Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res. 64:1008-1015.
13. Kaneko, S., et al. 2006. A selective Sema3A inhibitor enhances regenerative responses and functional recovery of the injured spinal cord. Nat. Med. 12:1380-1389. (Pubitemid 44924496)
14. Vacca, A., et al. 2006. Loss of inhibitory semaphorin 3A(SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma. Blood. 108:1661-1667. (Pubitemid 44316135)
15. Guttmann-Raviv, N., et al. 2007. Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J. Biol. Chem. 282:26294-26305. (Pubitemid 47443814)
16. Acevedo, L.M., Barillas, S., Weis, S.M., Gothert, J.R., and Cheresh, D.A. 2008. Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood. 111:2674-2680.
17. Zhou, Y., Gunput, R.A., and Pasterkamp, R.J. 2008. Semaphorin signaling: progress made and promises ahead. Trends Biochem. Sci. 33:161-170.
18. Narazaki, M., and Tosato, G. 2006. Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A. Blood. 107:3892-3901. (Pubitemid 43726793)
19. Damon, D.H. 2006. Vascular endothelial-derived semaphorin 3 inhibits sympathetic axon growth. Am. J. Physiol. Heart Circ. Physiol. 290:H1220-H1225.
20. Ito, T., et al. 2000. Repulsive axon guidance molecule Sema3A inhibits branching morphogenesis of fetal mouse lung. Mech. Dev. 97:35-45. (Pubitemid 30750556)
21. Kigel, B., Varshavsky, A., Kessler, O., and Neufeld, G. 2008. Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells. PLoS ONE. 3:e3287.
22. Christensen, C., et al. 2005. Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis. Cancer Res. 65:6167-6177. (Pubitemid 40994402)
23. Rolny, C., et al. 2008. The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. J. Exp. Med. 205:1155-1171. (Pubitemid 351679690)
24. Hanahan, D., and Folkman, J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353-364. (Pubitemid 26272076)
25. Hanahan, D. 1985. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature. 315:115-122. (Pubitemid 15064530)
26. Coussens, L.M., Hanahan, D., and Arbeit, J.M. 1996. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am. J. Pathol. 149:1899-1917. (Pubitemid 26415210)
27. Arbeit, J.M., Howley, P.M., and Hanahan, D. 1996. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 93:2930-2935. (Pubitemid 26114341)
28. Giraudo, E., Inoue, M., and Hanahan, D. 2004. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 114:623-633. (Pubitemid 39578752)
29. Bergers, G., Javaherian, K., Lo, K.M., Folkman, J., and Hanahan, D. 1999. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 284:808-812. (Pubitemid 29291347)
30. Guttmann-Raviv, N., et al. 2006. The neuropilins and their role in tumorigenesis and tumor progression. Cancer Lett. 231:1-11. (Pubitemid 41779447)
31. Herzog, Y., Kalcheim, C., Kahane, N., Reshef, R., and Neufeld, G. 2001. Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech. Dev. 109:115-119. (Pubitemid 33035924)
32. Toyofuku, T., et al. 2004. Dual roles of Sema6D in cardiac morphogenesis through region-specific association of its receptor, Plexin-A1, with off-track and vascular endothelial growth factor receptor type 2. Genes Dev. 18:435-447. (Pubitemid 38316350)
33. Roodink, I., et al. 2005. Plexin D1 expression is induced on tumor vasculature and tumor cells: a novel target for diagnosis and therapy? Cancer Res. 65:8317-8323. (Pubitemid 41330596)
34. Smith-McCune, K., Zhu, Y.H., Hanahan, D., and Arbeit, J. 1997. Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice. Cancer Res. 57:1294-1300. (Pubitemid 27152554)
35. Park, K., et al. 2008. Cancer gene therapy using adeno-associated virus vectors. Front. Biosci. 13:2653-2659. (Pubitemid 351611602)
36. Wang, Z., et al. 2006. Widespread and stable pancreatic gene transfer by adeno-associated virus vectors via different routes. Diabetes. 55:875-884. (Pubitemid 44100159)
37. Shirvan, A., et al. 1999. Semaphorins as mediators of neuronal apoptosis. J. Neurochem. 73:961-971.
38. Bagnard, D., et al. 2004. Differential MAP kinases activation during semaphorin3A-induced repulsion or apoptosis of neural progenitor cells. Mol. Cell. Neurosci. 25:722-731. (Pubitemid 38481479)
39. Paez-Ribes, M., et al. 2009. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 15:220-231.
40. Armulik, A., Abramsson, A., and Betsholtz, C. 2005. Endothelial/pericyte interactions. Circ. Res. 97:512-523.
41. Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., and Hanahan, D. 2003. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111:1287-1295. (Pubitemid 36554699)
42. Willett, C.G., et al. 2004. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10:145-147.
43. Hamzah, J., et al. 2008. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature. 453:410-414. (Pubitemid 351693122)
44. Yamagishi, H., Olson, E.N., and Srivastava, D. 2000. The basic helix-loop-helix transcription factor, dHAND, is required for vascular development. J. Clin. Invest. 105:261-270. (Pubitemid 30094445)
45. Hynes, R.O. 2002. A reevaluation of integrins as regulators of angiogenesis. Nat. Med. 8:918-921.
46. Serini, G., Valdembri, D., and Bussolino, F. 2006. Integrins and angiogenesis: a sticky business. Exp. Cell Res. 312:651-658.
47. Parsons-Wingerter, P., et al. 2005. Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors. Am. J. Pathol. 167:193-211.
48. Lenter, M., et al. 1993. A monoclonal antibody against an activation epitope on mouse integrin chain beta 1 blocks adhesion of lymphocytes to the endothelial integrin alpha 6 beta 1. Proc. Natl. Acad. Sci. U. S. A. 90:9051-9055. (Pubitemid 23306449)
49. Bazzoni, G., Shih, D.T., Buck, C.A., and Hemler, M.E. 1995. Monoclonal antibody 9EG7 defines a novel beta 1 integrin epitope induced by soluble ligand and manganese, but inhibited by calcium. J. Biol. Chem. 270:25570-25577.
50. Valentijn, A.J., Zouq, N., and Gilmore, A.P. 2004. Anoikis. Biochem. Soc. Trans. 32:421-425.
51. Abraham, S., Kogata, N., Fassler, R., and Adams, R.H. 2008. Integrin {beta}1 Subunit Controls Mural Cell Adhesion, Spreading, and Blood Vessel Wall Stability. Circ. Res. 102:562-570.
52. Kikuchi, K., et al. 2003. In vitro and in vivo characterization of a novel semaphorin 3A inhibitor, SM-216289 or xanthofulvin. J. Biol. Chem. 278:42985-42991. (Pubitemid 37345911)
53. Folkman, J., Watson, K., Ingber, D., and Hanahan, D. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 339:58-61. (Pubitemid 19115892)
54. Bergers, G., et al. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2:737-744. (Pubitemid 30768157)
55. Bielenberg, D.R., et al. 2004. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J. Clin. Invest. 114:1260-1271.
56. Bielenberg, D.R., and Klagsbrun, M. 2007. Targeting endothelial and tumor cells with semaphorins. Cancer Metastasis Rev. 26:421-431. (Pubitemid 350115126)
57. Joyce, J.A., et al. 2003. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 4:393-403.
58. Hoffman, J.A., et al. 2003. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell. 4:383-391.
59. Ryschich, E., et al. 2006. Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res. 66:198-211. (Pubitemid 43166026)
60. Neufeld, G., and Kessler, O. 2008. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat. Rev. Cancer. 8:632-645.
61. Futamura, M., et al. 2007. Possible role of semaphorin 3F, a candidate tumor suppressor gene at 3p21.3, in p53-regulated tumor angiogenesis suppression. Cancer Res. 67:1451-1460. (Pubitemid 46383370)
62. Hanson, J.A., et al. 2006. Gene promoter methylation in prostate tumor-associated stromal cells. J. Natl. Cancer Inst. 98:255-261.
63. Shih, T., and Lindley, C. 2006. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin. Ther. 28:1779-1802. (Pubitemid 46038527)
64. Fischer, C., Mazzone, M., Jonckx, B., and Carmeliet, P. 2008. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat. Rev. Cancer. 8:942-956.
65. Pan, Q., et al. 2007. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell. 11:53-67. (Pubitemid 46054517)
66. Stoeltzing, O., et al. 2003. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int. J. Cancer. 104:496-503. (Pubitemid 36323922)
67. Kim, S., Bakre, M., Yin, H., and Varner, J.A. 2002. Inhibition of endothelial cell survival and angiogenesis by protein kinase A. J. Clin. Invest. 110:933-941.
68. Song, S., Ewald, A.J., Stallcup, W., Werb, Z., and Bergers, G. 2005. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat. Cell Biol. 7:870-879. (Pubitemid 41486287)
69. Cary, S.P., Winger, J.A., Derbyshire, E.R., and Marletta, M.A. 2006. Nitric oxide signaling: no longer simply on or off. Trends Biochem. Sci. 31:231-239.
70. Kashiwagi, S., et al. 2008. Perivascular nitric oxide gradients normalize tumor vasculature. Nat. Med. 14:255-257. (Pubitemid 351347918)
71. Gao, G.P., et al. 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U. S. A. 99:11854-11859.